{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:05:55Z","timestamp":1773234355341,"version":"3.50.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.parkreldis.2004.10.004","type":"journal-article","created":{"date-parts":[[2005,2,11]],"date-time":"2005-02-11T04:36:33Z","timestamp":1108096593000},"page":"265-266","source":"Crossref","is-referenced-by-count":3,"title":["Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients"],"prefix":"10.1016","volume":"11","author":[{"given":"S.","family":"Papapetropoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"Argyriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.parkreldis.2004.10.004_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.parkreldis.2004.01.006","article-title":"Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline","volume":"10","author":"Kamakura","year":"2004","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.parkreldis.2004.10.004_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.parkreldis.2004.10.004_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases [see comments]","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2004.10.004_bib4","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC; 1994."},{"key":"10.1016\/j.parkreldis.2004.10.004_bib5","unstructured":"Fahn S, Elton RL. Members of the UPDRS development Committee. Unified Parkinson's disease rating scale. In: Recent developments in Parkinson's disease. Macmillan healthcare information; 1987. p. 153\u201363."},{"issue":"Pt 4","key":"10.1016\/j.parkreldis.2004.10.004_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors","volume":"123","author":"Fenelon","year":"2000","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.parkreldis.2004.10.004_bib7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":"Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.parkreldis.2004.10.004_bib8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","article-title":"Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group","volume":"42","author":"Parkinson Study Group","year":"1997","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.parkreldis.2004.10.004_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","article-title":"Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)","volume":"105","author":"Poewe","year":"2002","journal-title":"Acta Neurol Scand"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802004001609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802004001609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T19:29:33Z","timestamp":1548703773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802004001609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S1353802004001609"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2004.10.004","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}